Home » PHOSPHAGENICS GETS APPROVAL FOR TRIAL OF TRANSDERMAL INSULIN DELIVERY
PHOSPHAGENICS GETS APPROVAL FOR TRIAL OF TRANSDERMAL INSULIN DELIVERY
Phosphagenics has received approval to begin Phase I clinical trials of its transdermal insulin delivery product TPM-02/Insulin.
The product is being developed as a novel way of administering insulin to diabetics, and this trial -- which is planned to begin this month -- follows on from the successful preclinical trials that were reported on in May 2006.
In the proposed study, 20 healthy male volunteers will be randomly assigned to receive either TPM-02/Insulin or a placebo, applied in a single dose directly to the skin.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May